These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 8670578)

  • 1. Termination of disease-modifying drugs in psoriatic arthritis: study of 109 courses of treatment.
    Gómez-Vaquero C; Rodríguez-Moreno J; Ros S; Marcos R; Fiter J; Roig-Escofet D
    Br J Rheumatol; 1996 Jun; 35(6):564-7. PubMed ID: 8670578
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases.
    Ujfalussy I; Koó E; Seszták M; Gergely P
    Z Rheumatol; 2003 Apr; 62(2):155-60. PubMed ID: 12721703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Life-table analysis of cyclosporin A treatment in psoriatic arthritis: comparison with other disease-modifying antirheumatic drugs.
    Spadaro A; Taccari E; Mohtadi B; Riccieri V; Sensi F; Zoppini A
    Clin Exp Rheumatol; 1997; 15(6):609-14. PubMed ID: 9444416
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses.
    Aletaha D; Smolen JS
    Rheumatology (Oxford); 2002 Dec; 41(12):1367-74. PubMed ID: 12468815
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients.
    Simon D; Kleyer A; Bayat S; Tascilar K; Kampylafka E; Meinderink T; Schuster L; Petrov R; Liphardt AM; Rech J; Schett G; Hueber AJ
    Arthritis Res Ther; 2019 Jul; 21(1):162. PubMed ID: 31269973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-line csDMARD monotherapy drug retention in psoriatic arthritis: methotrexate outperforms sulfasalazine.
    Jacobs ME; Pouw JN; Welsing P; Radstake TRDJ; Leijten EFA
    Rheumatology (Oxford); 2021 Feb; 60(2):780-784. PubMed ID: 32797218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriatic Disease: Update on Traditional Disease-modifying Antirheumatic Drugs.
    Marchesoni A; Lubrano E; Cauli A; Ricci M; Manara M
    J Rheumatol Suppl; 2015 Nov; 93():61-4. PubMed ID: 26523060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease-modifying antirheumatic drug therapy for psoriatic arthritis.
    Salvarani C; Cantini F; Olivieri I
    Clin Exp Rheumatol; 2002; 20(6 Suppl 28):S71-5. PubMed ID: 12463452
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Longterm therapy of psoriatic arthritis: intramuscular gold or methotrexate?
    Lacaille D; Stein HB; Raboud J; Klinkhoff AV
    J Rheumatol; 2000 Aug; 27(8):1922-7. PubMed ID: 10955334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study.
    Schoels M; Kapral T; Stamm T; Smolen JS; Aletaha D
    Ann Rheum Dis; 2007 Aug; 66(8):1059-65. PubMed ID: 17307765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness and retention rates of methotrexate in psoriatic arthritis in comparison with methotrexate-treated patients with rheumatoid arthritis.
    Lie E; van der Heijde D; Uhlig T; Heiberg MS; Koldingsnes W; Rødevand E; Kaufmann C; Mikkelsen K; Kvien TK
    Ann Rheum Dis; 2010 Apr; 69(4):671-6. PubMed ID: 19740904
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of methotrexate co-medication in TNF-inhibitor treatment in patients with psoriatic arthritis: results from 440 patients included in the NOR-DMARD study.
    Fagerli KM; Lie E; van der Heijde D; Heiberg MS; Lexberg AS; Rødevand E; Kalstad S; Mikkelsen K; Kvien TK
    Ann Rheum Dis; 2014 Jan; 73(1):132-7. PubMed ID: 23291385
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of sulphasalazine plus methotrexate in rheumatoid arthritis.
    Islam MN; Alam MN; Haq SA; Moyenuzzaman M; Patwary MI; Rahman MH
    Bangladesh Med Res Counc Bull; 2000 Apr; 26(1):1-7. PubMed ID: 11192489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The actual role of therapy with traditional disease-modifying antirheumatic drugs in psoriatic arthritis.
    Soriano ER
    J Rheumatol Suppl; 2012 Jul; 89():67-70. PubMed ID: 22751597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Conventional DMARD therapy (methotrexate-sulphasalazine) may decrease the requirement of biologics in routine practice of ankylosing spondylitis patients: a real-life experience.
    Can M; Aydın SZ; Niğdelioğlu A; Atagündüz P; Direskeneli H
    Int J Rheum Dis; 2012 Dec; 15(6):526-30. PubMed ID: 23253235
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Termination of disease modifying antirheumatic drugs in psoriatic arthritis.
    Lacaille D; Stein HB; Raboud J; Klinkhoff AV
    J Rheumatol; 2002 Apr; 29(4):860-1. PubMed ID: 11950038
    [No Abstract]   [Full Text] [Related]  

  • 17. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs.
    Maetzel A; Wong A; Strand V; Tugwell P; Wells G; Bombardier C
    Rheumatology (Oxford); 2000 Sep; 39(9):975-81. PubMed ID: 10986302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study.
    van Halm VP; Nurmohamed MT; Twisk JW; Dijkmans BA; Voskuyl AE
    Arthritis Res Ther; 2006; 8(5):R151. PubMed ID: 16984661
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study.
    Aletaha D; Smolen JS
    J Rheumatol; 2002 Aug; 29(8):1631-8. PubMed ID: 12180721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions.
    Helliwell PS; Taylor WJ;
    J Rheumatol; 2008 Mar; 35(3):472-6. PubMed ID: 18203324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.